Pioneering Efforts Produce Regenerative Products
May 29, 2015
Tissue Regenix Wound Care Inc.
Diabetic patients suffering diabetic foot ulcers (wounds) are benefiting from pioneering efforts in wound therapy. Tissue Regenix, an international medical technology company is leading the development of a range of regenerative products to make specialized replacement tissue using biological (human & animal) materials.
The company offers an expanding roster of products based on their patented dCELL® decellularization technology to provide acellular tissue scaffolds which are not rejected by the patient’s body. DermaPure® is a new decellularized human dermis product from Tissue Regenix used by physicians to help promote wound healing. Initial clinical use has demonstrated that DermaPure® allografts may have scaffold characteristics – including elasticity, porosity and bio-compatibility – comparable to natural tissue, which have been shown to promote beneficial cellular activity during healing.
Clinical trials are an opportunity for patients to receive promising new therapies, but they can be difficult to navigate. Learn how The Leukemia & Lymphoma Society’s Clinical Trial Support Center is helping guide patients.
There are approximately 7,000 known rare diseases, but only 5% of them have an approved treatment. Learn how early intervention, proper management strategies, and clinical trials are key for rare disease patients.
Friedreich’s Ataxia is a progressive and debilitating neurological disorder. It's important to recognize symptoms and obtain an early diagnosis to properly manage the condition.